The Biggest Risk in BCI Isn't FDA Approval. It's Getting Paid for It

Most conversations about risk in brain-computer interfaces stop at the FDA. Will the device be approved. How long will the trial take. What does the breakthrough device pathway actually buy you. These are real questions, and founders spend years of runway answering them.

But approval is not the finish line. It's closer to the starting gun for a second race that gets far less attention, because a cleared device with nobody willing to pay for it is not a business. It's an expensive proof of concept.

Reimbursement in the United States runs through a system most engineers never have to think about until it's too late. A new procedure or device generally needs a billing code before a hospital can be paid to use it. Getting a permanent code assigned by CMS can take years, and it typically requires clinical and economic evidence that most companies haven't generated by the time they clear the FDA, because the trials built to satisfy regulators are not the same trials that satisfy payers. Regulators mostly want to know if a device is safe and does what it claims. Payers want to know if it's worth the money compared to whatever a hospital is already doing, and that is a fundamentally different question with a fundamentally different kind of evidence behind it.

This gap shows up constantly in medtech, and there is no reason BCI escapes it. A company can spend a decade and hundreds of millions of dollars getting an implant approved, launch to real excitement, and then discover that a temporary billing code, or a category that lumps a novel procedure in with something unrelated, means most hospitals lose money every time they perform it. When that happens, adoption doesn't fail loudly. It just quietly never happens. Surgeons who would refer patients don't, because the hospital's finance department won't sign off on a procedure that loses money at scale, no matter how promising it looked in a case study.

BCI has some features that make this worse than average, not better. Its earliest patient populations, people with ALS or severe paralysis, are often a small enough group that payers see limited pressure to move quickly. Its value is genuinely hard to quantify in the language payers understand, because restoring someone's ability to communicate does not map neatly onto the cost-offset models built for, say, reducing hospital readmissions. And because these are new procedures requiring specialized surgical teams, the true cost of delivering care is often higher and harder to predict than anyone selling the technology wants to admit up front.

None of this means reimbursement is unsolvable. It means it has to be treated as a design constraint from the beginning rather than a problem for the commercial team to figure out after launch.

Where this could be wrong

Breakthrough device and other expedited pathways increasingly come bundled with faster, sometimes provisional reimbursement decisions, which narrows this gap compared to a decade ago. Severe enough conditions can also generate real political and advocacy pressure, and payers do sometimes move faster when patient groups are vocal and sympathetic, which biases early BCI applications like ALS and paralysis in a helpful direction rather than a harmful one. There is also a growing appetite among some health systems to pay out of pocket or through value-based contracts for anything that clearly reduces long-term caregiving costs, which sidesteps the traditional coding process almost entirely. So this risk may shrink faster for BCI specifically than it has historically for other implantable technology.

What this means for founders

If you're building in this space, the health economics work should start roughly when the engineering does, not after the pivotal trial reads out. That means talking to payers early enough to understand what evidence would actually move them, designing trials that capture cost offsets and quality of life alongside the primary clinical endpoint, and building relationships with the hospital systems who will eventually have to justify paying for this procedure internally. It also means being honest about total cost of care, including the surgical team, the follow-up, and the software, rather than pricing around the device alone. The startups that win here may not be the ones with the cleanest regulatory story. They may be the ones who treated getting paid as seriously as they treated getting approved, and started early enough for it to matter.

WorldChangers is a BCI startup accelerator — at most 10 early-stage companies per batch. If you're building at the brain-machine boundary, applications for Batch 01 are open.